Document:

Exhibit 10.2

NEITHER THE SECURITIES  REPRESENTED HEREBY NOR THE SECURITIES  ISSUABLE UPON THE
EXERCISE  HEREOF  HAVE BEEN  REGISTERED  UNDER THE  SECURITIES  ACT OF 1933,  AS
AMENDED (THE  "SECURITIES  ACT"),  OR ANY STATE  SECURITIES  LAWS AND MAY NOT BE
OFFERED,  SOLD,  PLEDGED,  ASSIGNED,  OR  OTHERWISE  TRANSFERRED  UNLESS  (1)  A
REGISTRATION  STATEMENT WITH RESPECT  THERETO IS EFFECTIVE  UNDER THE SECURITIES
ACT AND ANY APPLICABLE  STATE  SECURITIES  LAWS, OR (2) THE COMPANY  RECEIVES AN
OPINION  OF COUNSEL TO THE  HOLDER OF THIS  WARRANT  OR SUCH  SECURITIES,  WHICH
COUNSEL  AND OPINION  ARE  REASONABLY  SATISFACTORY  TO THE  COMPANY,  THAT THIS
WARRANT OR SUCH  SECURITIES,  AS  APPLICABLE,  MAY BE  OFFERED,  SOLD,  PLEDGED,
ASSIGNED,  OR  OTHERWISE  TRANSFERRED  IN THE  MANNER  CONTEMPLATED  WITHOUT  AN
EFFECTIVE  REGISTRATION  STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE  STATE
SECURITIES LAWS.

        THE TRANSFER OF THIS WARRANT IS RESTRICTED AS DESCRIBED HEREIN.

                          SYNOVICS PHARMACEUTICALS INC.

                          WARRANTS FOR THE PURCHASE OF
              SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE

NO. ___________

      THIS CERTIFIES  that, for  consideration,  the receipt and  sufficiency of
which are hereby  acknowledged,  and other value received,  JOHN S. COPANOS (the
"HOLDER")  is  entitled  to  subscribe   for,   and  purchase   from,   SYNOVICS
PHARAMACEUTICALS  INC. a Nevada corporation (the "COMPANY"),  upon the terms and
conditions  set  forth  herein,  at any  time or from  time to time on or  after
_____________________, 2008 (the "EFFECTIVE TIME") until 5:00 P.M. New York City
local time on the  seventh  anniversary  of the  Effective  Time (the  "EXERCISE
PERIOD"), an aggregate of Two Million One Hundred Thousand (2,100,000) shares of
common  stock,  par value $0.001 per share (the "COMMON  STOCK") of the Company.
This Warrant is initially  exercisable  at $1.00 per share;  provided,  however,
that upon the occurrence of any of the events specified in Section 8 hereof, the
rights  granted by this Warrant,  including the exercise price and the number of
shares of Common Stock to be received upon such  exercise,  shall be adjusted as
therein  specified.  The term  "EXERCISE  PRICE"  shall mean,  depending  on the
context,  the  initial  exercise  price  (as set forth  above)  or the  adjusted
exercise price per share.

<PAGE>

      As used  herein,  the term  "THIS  WARRANT"  shall mean and  include  this
Warrant and any Warrant or Warrants  hereafter  issued as a  consequence  of the
exercise or transfer of this  Warrant in whole or in part.  Each share of Common
Stock issuable upon the exercise  hereof shall be  hereinafter  referred to as a
"WARRANT SHARE".

            1. (a)  Subject to the terms of this  Warrant,  this  Warrant may be
exercised  at any time in whole and from time to time in part,  at the option of
the  Holder,  on or after the  Effective  Time and on or prior to the end of the
Exercise  Period.  This Warrant shall  initially be  exercisable  in whole or in
part,  for  One  Million  Four  hundred  Thousand  (1,400,000)  fully  paid  and
nonassessable  shares of Common  Stock  and if Holder is still  employed  by the
Company  or any  subsidiary  of the  Company  on the  first  anniversary  of the
Effective  Date,  this Warrant shall be  exercisable in whole or in part, for an
additional Seven Hundred Thousand (700,000) fully paid and nonassessable  shares
of Common Stock, for an exercise price per share equal to the Exercise Price, by
delivery  to the  Company  at its  office at 5360  Northwest  35th  Avenue,  Ft.
Lauderdale, Fl. 33309, or at such other place as is designated in writing by the
Company, of:

             (i) a  completed  Election  to  Purchase,  in the form set forth in
      EXHIBIT I, executed by the Holder  exercising  all or part of the purchase
      rights represented by this Warrant;

            (ii) this Warrant;

            (iii) if this Warrant is not  registered  in the name of the initial
      registered  Holder,  an  assignment  in the form set forth in  EXHIBIT  II
      hereto  evidencing the  assignment of this Warrant to the current  Holder;
      and

            (iv) payment of an amount equal to the product of the Exercise Price
      multiplied  by the number of shares of Common Stock being  purchased  upon
      such exercise in the form of, at the Holder's  option,  (A) a certified or
      bank  cashier's  check  payable to the Company,  or (B) a wire transfer of
      funds to an account designated by the Company.

            Notwithstanding  anything  in this  Section  1(a)  to the  contrary,
      should  Ronald H. Lane be removed or resign  from the  Company's  Board of
      Directors all of the Warrant Shares shall vest as of the effective date of
      that removal or resignation.

      (b) As used herein:

            "FAIR  MARKET  VALUE" of a security  shall  mean,  on any given day,
shall mean the average of the  closing  prices of such  security's  sales on all
securities  exchanges  on which such  security may at the time be listed on such
day,  or,  if there  has been no sales on any such  exchange  on such  day,  the
average of the highest bid and lowest asked prices on all such  exchanges at the
end of such day, or, if on such day such security is not so listed,  the average
of the  representative  bid and  asked  prices  quoted  on the  over-the-counter
bulletin  board (the "OTCBB") as of 4:00 P.M., New York time, or, if on such day
such security is not quoted on the OTCBB, the average of the

                                     - 2 -
<PAGE>

highest bid and lowest asked prices on such day in the domestic over-the-counter
market as reported by the PinkSheet, LLC, or any similar successor organization.
If at any time such security is not listed on any securities  exchange or quoted
on the OTCBB or the over-the-counter market, the "Fair Market Value" shall be as
determined by the Board of Directors in good faith, absent manifest error.

      (c) Upon the exercise of this  Warrant,  the Company shall issue and cause
promptly to be delivered  upon such  exercise to, or upon the written  order of,
the Holder and in such name or names as the Holder may designate,  a certificate
or certificates for the number of full Warrant Shares to which such Holder shall
be  entitled,  together  with cash in lieu of any  fraction  of a Warrant  Share
otherwise issuable upon such exercise. Such certificate or certificates shall be
deemed to have been  issued,  and any person so  designated  to be the person or
persons  entitled to receive the Warrant  Shares  issuable upon exercise of this
Warrant shall be deemed to have become a holder of record of such Warrant Shares
for all  purposes,  as of the close of business on the date of the  surrender of
this Warrant and full payment of the Exercise Price.

      (d) If this  Warrant  is  exercised  in  respect  of less  than all of the
Warrant  Shares  evidenced  by this  Warrant at any time prior to the end of the
Exercise Period, a new Warrant  evidencing the remaining Warrant Shares shall be
issued to the Holder, or its nominee(s), without charge therefor.

      2. Upon each exercise of the Holder's  rights to purchase  Warrant Shares,
the  Holder  shall be deemed to be the holder of record of the  Warrant  Shares,
notwithstanding  that the transfer  books of the Company shall then be closed or
certificates  representing the Warrant Shares with respect to which this Warrant
was exercised shall not then have been actually delivered to the Holder. As soon
as practicable after each such exercise of this Warrant, the Company shall issue
and deliver to the Holder a certificate or certificates representing the Warrant
Shares issuable upon such exercise,  registered in the name of the Holder or its
designee.  If this Warrant  should be exercised in part only, the Company shall,
upon surrender of this Warrant for  cancellation,  execute and deliver a Warrant
evidencing  the right of the Holder to  purchase  the  balance of the  aggregate
number of Warrant Shares purchasable  hereunder as to which this Warrant has not
been exercised or assigned.

      3. Any  Warrants  issued  upon the  transfer  or  exercise in part of this
Warrant  shall be numbered and shall be  registered  in a warrant  register (the
"WARRANT  REGISTER") as they are issued.  The Company shall be entitled to treat
the  registered  holder of any Warrant on the  Warrant  Register as the owner in
fact thereof for all purposes, and shall not be bound to recognize any equitable
or other claim to, or interest in, such Warrant on the part of any other person,
and shall not be liable for any  registration  of transfer of Warrants which are
registered  or to be  registered  in the name of a fiduciary or the nominee of a
fiduciary  unless made with the actual  knowledge that a fiduciary or nominee is
committing a breach of trust in requesting  such  registration  or transfer,  or
with the knowledge of such facts that its  participation  therein amounts to bad
faith.  This Warrant shall be transferable on the books of the Company only upon
delivery thereof duly endorsed by the Holder or by his duly authorized  attorney
or representative, or accompanied by proper evidence of

                                     - 3 -
<PAGE>

succession, assignment, or authority to transfer. In all cases of transfer by an
attorney, executor, administrator, guardian, or other legal representative, duly
authenticated evidence of his, her, or its authority shall be produced. Upon any
registration of transfer, the Company shall deliver a new Warrant or Warrants to
the person entitled thereto. This Warrant may be exchanged, at the option of the
Holder   thereof,   for  another   Warrant,   or  other  Warrants  of  different
denominations,  of like tenor and  representing  in the  aggregate  the right to
purchase a like number of Warrant Shares (or portions  thereof),  upon surrender
to the Company or its duly authorized agent.  Notwithstanding the foregoing, the
Company  shall have no  obligation to cause  Warrants to be  transferred  on its
books to any person if, in the opinion of counsel to the Company,  such transfer
does not comply with the  provisions of the  Securities  Act of 1933, as amended
(the "SECURITIES ACT"), and the rules and regulations thereunder.

        4. The Company  shall pay all federal and state taxes  (other than taxes
on income of the Holder),  documentary  taxes,  stamp  taxes,  if any, and other
governmental  charges  that may be imposed upon the issuance or delivery of this
Warrant or upon the issuance or delivery of Warrant  Shares upon the exercise of
this Warrant,  PROVIDED,  HOWEVER, that the Company shall not be required to pay
any taxes  payable in connection  with any transfer  involved in the issuance or
delivery  of any  Warrants  or  Warrant  Shares in a name other than that of the
Holder in respect of which such  Warrant  Shares are  issued.  The  Company  may
refuse to deliver the certificates  representing the Warrant Shares being issued
in a name  other  than the  Holder's  name  until  the  Company  receives  a sum
sufficient  to pay any tax that will be due because such shares are to be issued
in a name other than the Holder's name.

        5. (a) The Company shall at all times reserve and keep  available out of
its  authorized and unissued  Common Stock,  solely for the purpose of providing
for the  exercise  of the  Warrants,  such  number of shares of Common  Stock as
shall, from time to time, be sufficient therefor. The Company covenants that all
Warrant  Shares  which may be issued upon the  exercise of the  purchase  rights
represented  by  this  Warrant  will,  upon  exercise  of  the  purchase  rights
represented by this Warrant, be duly authorized,  validly issued, fully paid and
nonassessable and free from all taxes, liens and charges in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue),  without any  personal  liability  attaching to the  ownership
thereof and will not be issued in violation of any  preemptive or similar rights
of stockholders. The Company further covenants that its issuance of this Warrant
shall constitute full authority to its officers who are charged with the duty of
executing stock certificates to execute and issue the necessary certificates for
the Warrant Shares upon the exercise of the purchase  rights under this Warrant.
The Company will take all such  reasonable  action as may be necessary to assure
that such Warrant Shares may be issued as provided  herein without  violation of
any applicable law or regulation,  or of any  requirements of the trading market
upon which the Common Stock may be listed.

      (b) The transfer agent for the Common Stock and every subsequent  transfer
agent for any of the  Company's  securities  issuable  upon the exercise of this
Warrant  shall be  irrevocably  authorized  and directed at all times to reserve
such number of authorized  securities as shall be required for such purpose. The
Company  shall keep a copy of this Warrant on file with the  transfer  agent for
the Common Stock and with every subsequent transfer agent for shares of

                                     - 4 -
<PAGE>

the Company's securities issuable upon the exercise of this Warrant. The Company
shall supply such transfer  agent with duly executed  certificates  representing
the Common Stock or other securities for such purposes.

      (c) The Company  shall not by any action  including,  without  limitation,
amending  its  certificate  of  incorporation  or  through  any  reorganization,
transfer  of  assets,  consolidation,  merger,  dissolution,  issue  or  sale of
securities or any other voluntary action,  avoid or seek to avoid the observance
or  performance  of any of the terms of this  Warrant;  but will at all times in
good faith assist in the carrying out of all such terms and in the taking of all
such  actions as may be necessary  or  appropriate  to protect the rights of the
Holder against impairment. Without limiting the generality of the foregoing, the
Company  will (a) not  increase  the par value of any  shares  of  Common  Stock
receivable  upon the exercise of this Warrant above the amount payable  therefor
upon such exercise immediately prior to such increase in par value, and (b) take
all such action as may be necessary or appropriate in order that the Company may
validly and legally  issue fully paid and  nonassessable  shares of Common Stock
upon the exercise of this Warrant.

      6. The  Company  will  obtain  and  keep  effective  any and all  permits,
consents and approvals of Federal or state governmental agencies and authorities
and make all filings under Federal and state  securities laws, that are required
in connection  with the issuance and delivery of this  Warrant,  the exercise of
this  Warrant,  and the issuance and delivery of the Warrant  Shares issued upon
exercise of this Warrant.

      7. If the Company  purchases  or  otherwise  acquires  this  Warrant,  the
Company shall cancel this  Warrant,  and any Warrant  surrendered  for exchange,
substitution, transfer or exercise in whole or in part.

      8. The Exercise  Price for the  Warrants in effect from time to time,  and
the number of Warrant  Shares  issuable upon exercise of the Warrants,  shall be
subject to adjustment as follows:

      (a) If the  Company,  at any time while this Warrant is  outstanding:  (A)
pays a stock  dividend or otherwise  make a  distribution  or  distributions  on
shares of its Common Stock or any other equity or equity  equivalent  securities
payable in shares of Common Stock  (which,  for  avoidance  of doubt,  shall not
include  any  shares of Common  Stock  issued by the  Company  pursuant  to this
Warrant), (B) subdivides outstanding shares of Common Stock into a larger number
of shares,  (C) combines  (including by way of reverse stock split)  outstanding
shares of  Common  Stock  into a smaller  number  of  shares,  or (D)  issues by
reclassification  of shares of the Common  Stock any shares of capital  stock of
the  Company,  then in each case the  Exercise  Price shall be  multiplied  by a
fraction of which the  numerator  shall be the number of shares of Common  Stock
(excluding  treasury shares, if any) outstanding  immediately  before such event
and of which the  denominator  shall be the  number  of  shares of Common  Stock
outstanding  immediately  after such event. Any adjustment made pursuant to this
Section 8(a) shall become  effective  immediately  after the record date for the
determination of stockholders  entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a
subdivision, combination or re-classification.

                                     - 5 -
<PAGE>

      (b) When any  adjustment  is  required  to be made in the  Exercise  Price
pursuant to subsection  8(a), the number of Warrant Shares  purchasable upon the
exercise of this Warrant  shall be changed to the number  determined by dividing
(i) an  amount  equal to  product  of the  number of  shares  issuable  upon the
exercise of this Warrant immediately prior to such adjustment  multiplied by the
Exercise  Price in  effect  immediately  prior to such  adjustment,  by (ii) the
Exercise Price in effect immediately after such adjustment.

      (c) Notwithstanding anything herein to the contrary, if the Company issues
warrants in connection  with its next round of financing of at least  $5,000,000
and those  warrants  have an exercise  price less than the Exercise  Price,  the
Exercise Price shall automatically be reduced to that lower exercise price.

      (d) Upon the occurrence of each adjustment or readjustment of the Exercise
Price pursuant to this Section 8, the Company at its expense shall,  as promptly
as  reasonably  practicable  but in any event not later than  fifteen  (15) days
thereafter, compute such adjustment or readjustment in accordance with the terms
hereof and furnish to the Holder a certificate  setting forth such adjustment or
readjustment  (including  the  kind  and  amount  of  securities,  cash or other
property for which this Warrant shall be exercisable and the Exercise Price) and
showing in detail the facts upon which such adjustment or readjustment is based.
The  Company  shall,  as promptly as  reasonably  practicable  after the written
request  at any time of the  Holder  (but in any event  not  later  than 15 days
thereafter),  furnish  or  cause to be  furnished  to the  Holder a  certificate
setting  forth (i) the  Exercise  Price  then in effect  and (ii) the number and
class or series of Warrant Shares and the amount,  if any, of other  securities,
cash or property which then would be received upon the exercise of this Warrant.

      (e) All  calculations  under this  Section 8 shall be made to the  nearest
cent or the nearest 1/100th of a share, as the case may be.

      (f) The Company shall not be required upon the exercise of this Warrant to
issue any  fractional  shares,  but shall pay the value thereof to the Holder in
cash on the basis of the Fair Market  Value per  Warrant  Share,  as  determined
pursuant to subsection 1(b) above.

      9. (a) Unless  registered,  the Warrant  Shares  issued on exercise of the
Warrants  shall be  subject  to a stop  transfer  order and the  certificate  or
certificates representing the Warrant Shares shall bear the following legend:

      THE  SECURITIES  REPRESENTED  HEREBY  HAVE NOT BEEN  REGISTERED  UNDER THE
      SECURITIES ACT OF 1933, AS AMENDED (THE  "SECURITIES  ACT"),  OR ANY STATE
      SECURITIES  LAWS  AND MAY NOT BE  OFFERED,  SOLD,  PLEDGED,  ASSIGNED,  OR
      OTHERWISE  TRANSFERRED  UNLESS (1) A  REGISTRATION  STATEMENT WITH RESPECT
      THERETO IS EFFECTIVE  UNDER THE SECURITIES  ACT AND ANY  APPLICABLE  STATE
      SECURITIES  LAWS, OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE
      HOLDER OF SUCH  SECURITIES,  WHICH  COUNSEL  AND  OPINION  ARE  REASONABLY
      SATISFACTORY  TO  THE  COMPANY,  THAT  SECURITIES  MAY

                                     - 6 -
<PAGE>

      BE OFFERED,  SOLD,  PLEDGED,  ASSIGNED,  OR OTHERWISE  TRANSFERRED  IN THE
      MANNER CONTEMPLATED WITHOUT AN EFFECTIVE  REGISTRATION STATEMENT UNDER THE
      SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS.

      THIS  CERTIFICATE ALSO EVIDENCES AND ENTITLES THE HOLDER HEREOF TO CERTAIN
      RIGHTS AS SET FORTH IN THE RIGHTS  AGREEMENT,  AS IT MAY FROM TIME TO TIME
      BE SUPPLEMENTED OR AMENDED,  BETWEEN  SYNOVICS  PHARMACEUTICALS,  INC. AND
      CONTINENTAL STOCK TRANSFER & TRUST COMPANY,  THE TERMS OF WHICH ARE HEREBY
      INCORPORATED  HEREIN  BY  REFERENCE  AND A COPY OF WHICH IS ON FILE AT THE
      PRINCIPAL  EXECUTIVE  OFFICES  OF  SYNOVICS  PHARMACEUTICALS,  INC.  UNDER
      CERTAIN CIRCUMSTANCES,  AS SET FORTH IN THE RIGHTS AGREEMENT,  SUCH RIGHTS
      MAY BE REDEEMED OR EXCHANGED,  MAY EXPIRE, OR MAY BE EVIDENCED BY SEPARATE
      CERTIFICATES  AND NO LONGER BE  EVIDENCED  BY THIS  CERTIFICATE.  SYNOVICS
      PHARMACEUTICALS,  INC. WILL MAIL TO THE HOLDER OF THIS  CERTIFICATE A COPY
      OF THE RIGHTS AGREEMENT WITHOUT CHARGE WITHIN FIVE DAYS AFTER RECEIPT OF A
      WRITTEN REQUEST THEREFOR.  UNDER CERTAIN CIRCUMSTANCES,  RIGHTS ISSUED TO,
      OR HELD BY,  ACQUIRING  PERSONS OR THEIR  AFFILIATES OR ASSOCIATES AND ANY
      SUBSEQUENT HOLDER OF SUCH RIGHTS MAY BECOME NULL AND VOID."

            (b) The Company  represents  and warrants to the Holder that it will
include the Warrant Shares in its next registration,  subject only to reasonable
cutbacks that may be required by the investor or investor group whose shares are
also being registered.

      10. The  Company  covenants  that upon  receipt by the Company of evidence
reasonably  satisfactory to it of the loss, theft,  destruction or mutilation of
this Warrant or any stock  certificate  relating to the Warrant  Shares,  and in
case of  loss,  theft  or  destruction,  of  indemnity  or  security  reasonably
satisfactory to it, and upon surrender and cancellation of such Warrant or stock
certificate,  if  mutilated,  the Company will make and deliver a new Warrant or
stock certificate of like date, tenor and denomination,  in lieu of such Warrant
or stock certificate

      11. (a) The  Holder of any  Warrant  shall not have,  solely on account of
such status,  any rights of a  stockholder  of the Company,  either at law or in
equity, or to any notice of meetings of stockholders or of any other proceedings
of the Company, except as provided in this Warrant.

            (b) No provision  hereof,  in the absence of  affirmative  action by
Holder to Warrant Shares,  and no enumeration herein of the rights or privileges
of Holder  hereof,  shall  give rise to any  liability  of such  Holder  for the
purchase price of any Common Stock or as a stockholder of Company,  whether such
liability is asserted by Company or by creditors of Company.

                                     - 7 -
<PAGE>

      12. Promptly upon the appointment of any subsequent  transfer agent of the
Common  Stock,  or any  other  securities  issuable  upon the  exercise  of this
Warrant,  the Company will deliver to the Holder a statement  setting  forth the
name and address of such subsequent transfer agent.

      13.  All  notices  and  other  communications  provided  for or  permitted
hereunder  shall be in writing and shall be deemed given (i) when made,  if made
by hand delivery,  (ii) upon confirmation,  if made by telecopier,  or (iii) one
business day after being deposited with a reputable  next-day  courier,  postage
prepaid, to the parties as follows:

                  if to the Company:

                  5360 Northwest 35th Ave.
                  Fort Lauderdale, FL 33309
                  Attention: Ronald H. Lane Ph.D.
                  Telecopy: (954) 486 4590

                  if to the Holder:

                  As set forth in the Warrant Register of the Company.

            The Company or the Holder by notice to the other party may designate
additional  or  different  addresses  as shall be  furnished  in writing by such
party. Any notice or communication mailed to the Holder shall be mailed by first
class  mail or other  equivalent  means at such  Holder's  address  and shall be
sufficiently given to such Holder if so mailed within the time prescribed.

      14. The Company and the Holder may from time to time supplement, modify or
amend this  Warrant,  except,  this  Warrant  may not be  amended,  modified  or
supplemented,  and waivers or consents to departures from the provisions  hereof
may not be given, without the written consent of the Company and Holder.

      15. All the covenants and provisions of this Warrant by or for the benefit
of the  Company  or the  Holder  shall be  binding  upon and shall  inure to the
benefit of their respective permitted successors and assigns hereunder.

      16.  The  Company  shall not merge or  consolidate  with or into any other
entity unless the entity resulting from such merger or consolidation (if not the
Company) shall expressly assume, by supplemental  agreement satisfactory in form
to the Holder and  executed and  delivered  to the Holder,  the due and punctual
performance  and  observance  of each and every  covenant and  condition of this
Warrant to be performed and observed by the Company.

      17. The validity,  interpretation and performance of this warrant shall be
governed by the laws of the State of Florida,  as applied to contracts  made and
performed within the state of Florida, without regard to principles of conflicts
of  law.  Each  of the  parties  hereto  irrevocably  submits  to the  exclusive
jurisdiction  of the  courts  of the  State of  Florida  and the  United  States

                                     - 8 -
<PAGE>

District Court for the Southern District of Florida, in each case sitting in the
County of Broward,  for the purpose of any suit, action,  proceeding or judgment
relating  to or  arising  out of this  letter  agreement.  Service of process in
connection with any such suit,  action or proceeding may be served on each party
hereto anywhere in the world by the same methods as are specified for the giving
of notices under this Warrant.  Each of the parties hereto irrevocably  consents
to the jurisdiction of any such court in any such suit, action or proceeding and
to the laying of venue in such court. Each party hereto  irrevocably  waives any
objection to the laying of venue of any such suit, action or proceeding  brought
in such courts and  irrevocably  waives any claim that any such suit,  action or
proceeding brought in any such court has been brought in an inconvenient forum.

      18. The provisions hereof have been and are made solely for the benefit of
the Company and the Holder, and their respective  successors and assigns, and no
other person shall acquire or have any right hereunder or by virtue hereof.

      19. The  headings in this Warrant are for  convenience  only and shall not
limit or otherwise affect the meaning hereof.

      20. If any term,  provision,  covenant or  restriction  of this Warrant is
held by a court  of  competent  jurisdiction  to be  invalid,  illegal,  void or
unenforceable,   the   remainder  of  the  terms,   provisions,   covenants  and
restrictions set forth herein shall remain in full force and effect and shall in
no way be affected,  impaired or  invalidated,  and the parties hereto shall use
their best efforts to find and employ an  alternative  means to achieve the same
or substantially the same result as that  contemplated by such term,  provision,
covenant  or  restriction.  It is  hereby  stipulated  and  declared  to be  the
intention of the parties  that they would have  executed  the  remaining  terms,
provisions,  covenants and restrictions  without including any of such which may
be hereafter declared invalid, illegal, void or unenforceable.

      21. This Warrant is intended by the parties as a final expression of their
agreement and intended to be a complete and exclusive statement of the agreement
and  understanding  of the  parties  hereto in  respect  of the  subject  matter
contained herein and therein. There are no restrictions, promises, warranties or
undertakings, other than those set forth or referred to herein and therein. This
Warrant supersedes all prior agreements and  understandings  between the parties
with respect to such subject matter.

      22. Each party hereto agrees to use all  reasonable  efforts to obtain all
consents  and  approvals,  and  to  do  all  other  things,  necessary  for  the
transactions contemplated by this Warrant on or prior to the end of the Exercise
Period. The parties agree to take such further action and to deliver or cause to
be delivered to each other after the date hereof such  additional  agreements or
instruments  as any of them may  reasonably  request for the purpose of carrying
out this Warrant and the agreements  and  transactions  contemplated  hereby and
thereby.

                                     - 9 -
<PAGE>

Dated: _________________, 2008

                                             SYNOVICS PHARMACEUTICALS, INC.

                                             BY: _______________________________
                                                 NAME: RONALD H. LANE
                                                 TITLE: CHAIRMAN & CEO

[Seal]

______________________
Secretary

                                     - 10 -
<PAGE>

EXHIBIT I

                              ELECTION TO PURCHASE

            The  undersigned  hereby  irrevocably  elects to  exercise  Warrants
represented  by this Warrant and to purchase the shares of Common Stock or other
securities  issuable  upon the  exercise of said  Warrants,  and  requests  that
Certificates for such shares be issued and delivered as follows:

ISSUE TO:
                  ---------------------------------------------
                  (Name)

                  ---------------------------------------------
                  (Address, Including Zip Code)

                  ---------------------------------------------
                  (Social Security or Tax Identification Number)

DELIVER TO:
                  ---------------------------------------------
                  (Name)

                  ---------------------------------------------
                  (Address, Including Zip Code)

            In  payment of the  purchase  price  with  respect  to this  Warrant
exercised,  the  undersigned  hereby  tenders  payment  of  $            by  (i)
certified  or bank  cashiers  check  payable to the order of the Company [ ]; or
(ii) a wire  transfer of such funds to an account  designated by the Company [ ]
(CHECK  APPLICABLE  BOX). If the number of Warrant  Shares  hereby  exercised is
fewer than all the Warrant Shares  represented by this Warrant,  the undersigned
requests that a new Warrant  representing  the number of full Warrant Shares not
exercised to be issued and delivered as set forth below:

Name of Holder or Assignee:
                            ------------------------------
                            (Please Print)

Address:
         ---------------------------------------------

         ---------------------------------------------

Signature:                                 DATED:                 , 200
          ------------------------------         -----------------     --
(Signature must conform in all respects to name of holder as specified on the
fact of this Warrant)

Signature Guaranteed:
                       -------------------------------

<PAGE>

EXHIBIT II

                                   ASSIGNMENT

            FOR VALUE  RECEIVED,  the  undersigned  hereby  sells,  assigns  and
transfers  unto the  Assignee  named below all of the rights of the  undersigned
represented by the within Warrant,  with respect to the number of Warrant Shares
set forth below:

                                                                  TAXPAYER
                                              NUMBER OF        IDENTIFICATION
NAME OF ASSIGNEE     ADDRESS               WARRANT SHARES          NUMBER
----------------     -------               --------------          ------

and  does  hereby  irrevocably   constitute  and  appoint   ___________________,
Attorney,  to make such  transfer  on the  Warrant  Register  maintained  at the
principal office of the Company with full power of substitution in the premises.

Dated:                        200
        ----------------------   --                   ------------------
        Signature
(Signature  must  conform in all  respects to name of holder as specified on the
face of this Warrant).

Signature Guaranteed:

--------------------------------------------------------------------------------Exhibit 10.3

      CONFIDENTIAL TREATMENT REQUEST

      [ * ] INDICATES INFORMATION THAT HAS BEEN OMITTED PURSUANT TO A
      CONFIDENTIAL TREATMENT REQUEST AND THIS INFORMATION HAS BEEN FILED UNDER
      SEPARATE COVER WITH THE COMMISSION.

                             SECOND SUPPLY AGREEMENT

      THIS SUPPLY AGREEMENT ("Agreement") made as of the 1st day of February
2008, between ANDAPHARM LLC, a Florida limited liability company having its
principal place of business at 5315 NW 35th Terrace, Fort Lauderdale, Florida
33309 ("ANDAPHARM") and Breckenridge Pharmaceutical, Inc. having its principal
place of business at 1141 S. Rogers Circle, Boca Raton, FL 33487
("BRECKENRIDGE").

                                    RECITALS

      A.    WHEREAS, ANDAPHARM is engaged in the business of developing,
            manufacturing, and selling pharmaceutical products;

      B.    WHEREAS, BRECKENRIDGE is engaged in the business of developing,
            marketing and distributing pharmaceutical products;

      C.    WHEREAS ANDAPHARM agrees to supply commercial quantities of the
            designated products exclusively to and on behalf of BRECKENRIDGE,
            subject to other terms herein.

      D.    BRECKENRIDGE agrees to purchase from ANDAPHARM commercial supplies
            of the designated products.

      E.    WHEREAS ANDAPHARM and BRECKENRIDGE entered into a Supply Agreement
            on March 13, 2007, pursuant to which ANDAPHARM agreed to supply
            [   *   *   ] to BRECKENRIDGE (the "Original Supply Agreement");

      F.    WHEREAS, ANDAPHARM and BRECKENRIDGE desire to agree upon new terms,
            whereby ANDAPHARM will supply [   *   ] to Breckenridge as set forth
            herein, and which shall supercede the Original Supply Agreement; and

      NOW, THEREFORE, in consideration of the mutual covenants set forth herein,
the receipt and sufficiency of which are hereby acknowledged, the parties
hereto, each intending to be legally bound, hereby agree as follows:

                             ARTICLE 1 - DEFINITIONS

1.1   "AFFILIATE" of a party means any Person directly or indirectly controlled
      by, controlling or under common control with such party. "CONTROL" means
      the legal power to direct or cause the direction of the general management
      or policies of a Person through more than fifty percent (50%) of the
      ownership of voting securities, by contract or by other means.

1.2   THE PRODUCT(S). The "Product(s)" shall mean the Product(s) listed in
      EXHIBIT A. Products(s) may be added to EXHIBIT A by written agreement of
      the parties.

1.3   THE FDA. The "FDA" shall mean the United States Food and Drug
      Administration.

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
<PAGE>

1.4   PURCHASE TERM. The "Purchase Term" shall mean the [ * ] period that begins
      on the date this agreement is signed. In the event that neither party
      gives the other written notice [ * ] months prior to the end of the
      initial [ * ] Purchase Term, the Agreement shall automatically be extended
      for successive [ * ] terms.

1.5   PURCHASE PRICE. The "Purchase Price" shall mean the price per unit as
      specified in EXHIBIT A hereof and subject to adjustment in accordance with
      Paragraph 2.2.

                          ARTICLE 2 - SUPPLY & PURCHASE

2.1   MANUFACTURE AND SUPPLY OF PRODUCT. Subject to the terms of this Agreement,
      ANDAPHARM shall [   *   ] to manufacture, package, and supply the Product
      to BRECKENRIDGE, subject to other terms herein. All Products shall be
      supplied by ANDAPHARM in accordance with accepted purchase orders received
      from BRECKENRIDGE. In consideration of ANDAPHARM's commitments in this
      Agreement, BRECKENRIDGE shall purchase from ANDAPHARM the minimum annual
      requirement listed on EXHIBIT A, as provided herein. The minimum annual
      requirement period shall commence [   *   ]  [   *   ]. In its sole
      discretion, BRECKENRIDGE shall be permitted to have the Product
      manufactured for and supplied to its Affiliate, who is qualified to
      receive the Product and [   *   ].

            (a)   LABELING AND PACKAGING. With the exception of label artwork,
            which shall be provided by BRECKENRIDGE, ANDAPHARM shall be solely
            responsible for the procuring of materials and API, packaging,
            labeling, performing all applicable analytical release testing, and
            otherwise preparing for delivery of the Product in accordance with
            the specifications agreed upon by the parties, as well as applicable
            federal and state regulations, including, without limitation, cGMP's
            relating to the FDA. ANDAPHARM shall perform all of the above
            services for product samples except for labels, labeling, and
            packaging. API shall be ordered from a supplier providing a suitable
            Certificate of Analysis demonstrating compliance with the required
            Specifications. Andapharm shall be responsible for all costs
            relating to [ * ]; however, in the event that Breckenridge requests
            more than [     *     ], it shall be charged [ * ];

                  i)  [     *     ]

                  ii) [     *     ]

            (b)   DATING. All Product shipped on behalf of BRECKENRIDGE, on the
            date of shipment by ANDAPHARM, shall have a shelf-life of at least
            [ * ] months, but

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        2
<PAGE>

            only if the stability testing results support a minimum of a [ * ]
            month shelf-life.

            (c) LIMITED EXCLUSIVITY. ANDAPHARM shall not be obligated to, and
            will not, manufacture and supply the Product to any third party
            during the Term, except to [    *    ].

2.2   PURCHASE ORDERS AND PRICE. $ [  *  ] of [ * ] as described in Exhibit A.
      Breckenridge shall make all purchases hereunder by submitting to Andapharm
      written purchase orders. Each Purchase Order shall be in batch-size
      multiples of [ * ] bottles with a minimum [ * ] day delivery date.
      Andapharm shall notify Breckenridge within [ * ] days of receipt of
      Purchase Order if it cannot fulfill Breckenridge's requirements contained
      therein.

      The initial purchase prices for the Products purchased under this
      Agreement shall be those set forth on EXHIBIT A. The parties agree to
      cooperate in adjusting prices due to [              *             ]
      ANDAPHARM agrees to provide documentation for such costs, if requested by
      Breckenridge. [   *   ], price increase for the finished-good Product
      shall not exceed [   *   ]. Any change contemplated herein shall be
      mutually agreed upon by the parties hereto and memorialized in a writing
      signed by both ANDAPHARM and BRECKENRIDGE. After [ * ] of the Purchase
      Term, this Agreement may be terminated by either party with [ * ] days
      written notice if a price adjustment cannot be mutually agreed upon and
      assuming any such proposed adjustments are commercially reasonable.

2.3   DELIVERY. Delivery shall be [   *   ], or to any other location in
      [    *    *    ], no later than the delivery date specified by
      BRECKENRIDGE, but, in no event, later than [ * ] days from the date of
      manufacture.

2.4   BILLING AND PAYMENT. ANDAPHARM shall invoice BRECKENRIDGE the Purchase
      Price for all units in each shipment of Products delivered to
      BRECKENRIDGE. Payment terms shall be as per section 2.5.

2.5   PREPAYMENT OF API. Breckenridge agrees to prepay, subject to pricing
      fluctuations, the cost of API at [ * ] per [   *   ].

                  ARTICLE 3 - QUALITY AND REGULATORY COMPLIANCE

3.1   QUALITY CONTROL. Each shipment of the Product to BRECKENRIDGE shall be
      accompanied by a Certificate of Analysis prepared by an authorized
      representative of ANDAPHARM certifying that the Product in the shipment
      has been tested in accordance with the specifications for the Product and
      was manufactured in compliance with cGMP. ANDAPHARM will send a copy of
      the Certificate of Analysis with each shipment to BRECKENRIDGE, and the
      original will be filed at ANDAPHARM, but shall be made

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        3
<PAGE>

      available to BRECKENRIDGE upon request.

            (a) Each lot of the Product shall be manufactured according the
            specifications mutually agreed upon between the parties. ANDAPHARM
            shall promptly notify BRECKENRIDGE in writing prior to instituting
            any changes to the specifications for the Product;

            (b) ANDAPHARM shall be permitted to subcontract some portions of the
            work contemplated by this Agreement to a third party upon first
            obtaining prior written consent from BRECKENRIDGE, which shall not
            be unreasonably withheld. Notwithstanding the preceding sentence,
            ANDAPHARM shall remain solely responsible for executing and
            monitoring the work performed by such subcontractors, including cGMP
            compliance of such subcontractor(s), pursuant to the terms of this
            Agreement. In addition, ANDAPHARM may subcontract packaging to Kirk
            Pharmaceuticals without the consent of BRECKENRIDGE.

3.2   REJECTION. Provided BRECKENRIDGE provides valid testing methods and
      protocols to ANDAPHARM, BRECKENRIDGE may examine and test Products as it
      sees fit. If BRECKENRIDGE finds that any lot of the Product, or part
      thereof, fails to conform to agreed specifications or other
      representations and warranties given by ANDAPHARM herein, then
      BRECKENRIDGE will notify ANDAPHARM within [   *   ] days of receipt of the
      Product, specifying the manner in which all or part of such shipment fails
      to meet the required specifications. If BRECKENRIDGE rejects a shipment
      before payment is due, [   *   ]. If BRECKENRIDGE rejects a shipment after
      payment has been made, [   *   ].

3.3   RECALLS. If any Product is recalled [   *   ], then [   *   ] shall bear
      all   [   *   ]. If the recalled Products are to be destroyed and the
      recall is due to [ * ] ANDAPHARM, at BRECKENRIDGE's request, shall
      [   *   ]. If such a recall is due to [   *   ], then BRECKENRIDGE shall
      [   *   ]. In no event shall [   *   ] be responsible for any [   *   ]
      incurred by [   *   ]. The parties agree to cooperate in case of a recall
      of any of the Products and provide such information as may be necessary to
      effectuate the recall and to satisfy any

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        4
<PAGE>

      regulatory requests about the recall.

3.4   DISPUTES. If ANDAPHARM disputes BRECKENRIDGE's right to reject all or part
      of any shipment of the Products as set forth in Paragraph 3.2 or
      BRECKENRIDGE's decision to recall any Product pursuant to paragraph 3.3
      hereof (except where requested by FDA to do so), such dispute shall be
      resolved by the decision of an independent testing organization or
      consultant mutually agreed upon by the parties to act as an arbitrator,
      the appointment of which shall not be unreasonably withheld or delayed by
      either party. The determination of such entity with respect to all or part
      of any shipment of the Products shall be final and binding upon the
      parties and enforceable in any court of competent jurisdiction,
      [         *         ]. The fees and expenses of the third party making the
      determination shall be paid by the party against which the determination
      is made. If the parties cannot agree to the independent testing
      organization or consultant to act as arbitrator within 30 days after
      notice of the dispute by either party to the other with a request to
      exercise this provision, the parties may proceed with their respective
      rights and remedies under Florida law.

3.5   INSPECTION. BRECKENRIDGE shall have the right, at its sole cost and
      expense, to enter and inspect Andapharm's premises upon reasonable notice
      during normal business hours for the purpose of inspecting the facilities,
      procedures and any relevant records relating to the manufacture of Product
      (including but not limited to, all batch sheets and records for all
      manufacturing steps), during the Term of this Agreement. In addition,
      BRECKENRIDGE shall have the right, at its sole cost and expense, to be
      present during the manufacture of Product, upon reasonable advance notice
      to ANDAPHARM. In the event that any of ANDAPHARM's Facilities used in the
      manufacturing of Product hereunder are inspected by representatives of any
      U.S. federal, state or local regulatory agency in connection with
      ANDAPHARM's manufacture of the Product, ANDAPHARM shall notify
      BRECKENRIDGE immediately by telephone, in advance of the inspection when
      practicable but in no event later than three (3) days after inspection and
      follow up in writing, upon learning of such inspection, and shall supply
      BRECKENRIDGE, no later than three (3) days after receipt by ANDAPHARM,
      with copies of any reports or responses including, but not limited to any
      Form 483s, Establishment Inspection Reports (EIRs), or Warning Letters
      prepared by the agency or ANDAPHARM relating to such inspection.

3.6   MANUFACTURING RECORDS. ANDAPHARM shall maintain adequate and accurate
      books and records in accordance with FDA requirements. ANDAPHARM agrees
      that its quality assurance staff shall review the manufacturing records
      for all steps and all lots of Product it manufactures hereunder. Upon
      discovery of any deviation from GMP or from any warranty hereunder
      ANDAPHARM shall conduct promptly an appropriate investigation to determine
      the cause of such deviation and take appropriate action at its expense to
      avoid recurrence. ANDAPHARM shall provide a copy of any such investigation
      report to BRECKENRIDGE.

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        5
<PAGE>

3.7   REGULATORY AGENCY COMMUNICATION. Each party will promptly notify but in no
      event later than [ * ] days of receipt the other party of, and provide the
      other party with copies of, any correspondence and/or other documentation
      received or prepared by the party in connection with (1) receipt of any
      warning letter or other regulatory correspondence from the FDA or any
      other regulatory authority in connection with the manufacture, packaging
      and storage of the Product; or (2) any recall of the Product; provided
      that a party may redact from such communications portions thereof which
      the party is required to keep confidential pursuant to binding agreements
      with third parties.

3.8   REGULATORY APPROVAL. In the event ANDAPHARM files an application with the
      FDA seeking approval for the Product, [       *       ].

                   ARTICLE 4 - REPRESENTATIONS AND WARRANTIES

4.1   JOINT REPRESENTATIONS AND WARRANTIES. Each party represents to the other
      that it will not take any action, or fail to take any action, that would
      cause a violation of the Federal Food Drug and Cosmetic Act, or any other
      Federal, State or local law or regulation during the term of this
      contract.

4.2   REPRESENTATIONS AND WARRANTIES OF BRECKENRIDGE. ANDAPHARM is entering into
      this Agreement in reliance upon the following express representations and
      warranties, each of which is made by BRECKENRIDGE:

      (a) NO CONFLICTS. BRECKENRIDGE represents and warrants that neither this
      Agreement, nor the carrying out of the terms and conditions that are
      contemplated by this Agreement, will violate the rights of any other party
      or result in the creation of any right or claim that may adversely affect
      BRECKENRIDGE's performance of its obligations under this Agreement.

      (b) AUTHORITY. BRECKENRIDGE warrants, represents and covenants that
      BRECKENRIDGE has the legal right to enter into this Agreement and perform
      its obligations hereunder. In addition, the undersigned signatory for
      BRECKENRIDGE represents and warrants that he has been duly authorized to
      sign this Agreement on behalf of BRECKENRIDGE and he further represents
      that all requisite corporate and partnership action has been taken on the
      part of BRECKENRIDGE to approve this Agreement.

      (c) REGULATORY COMPLIANCE. BRECKENRIDGE will comply with all applicable
      United States and state laws, statutes, rules, and regulations, including
      applicable current FDA guidelines. Without limitation, BRECKENRIDGE shall
      be responsible for obtaining all necessary permissions and licenses for
      the sale and distribution of Product, in accordance with the applicable
      United States and state laws, statutes, rules, and

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        6
<PAGE>

      regulations;

      (d) DEBARMENT. To the best of BRECKENRIDGE's knowledge, it has not and
      will not use the services of any persons debarred under 21 U.S.C. Section
      335(a) or (b) in any capacity associated with or related to the
      manufacture of the Product. BRECKENRIDGE also warrants that neither
      BRECKENRIDGE nor any of its officers or employees has been convicted of a
      felony under the U.S. federal law for conduct relating to the development
      or approval, including the process for development or approval, of any
      drug product, new drug application or abbreviated new drug application and
      neither BRECKENRIDGE nor any of its officers or employees has been
      convicted of a felony under the U.S. federal law for conduct relating to
      the regulation of any product under the Federal Food, Drug and Cosmetic
      Act. If required, BRECKENRIDGE shall provide for FDA submission a standard
      "Debarment Certification" upon request of ANDAPHARM.

4.3   REPRESENTATIONS AND WARRANTIES BY ANDAPHARM. BRECKENRIDGE is entering into
      this Agreement in reliance upon the following express representations and
      warranties, each of which is made by ANDAPHARM:

      (a) NO CONFLICTS. ANDAPHARM represents and warrants that neither this
      Agreement, nor the carrying out of the terms and conditions that are
      contemplated by this Agreement, will violate the rights of any other party
      or result in the creation of any right or claim that may adversely affect
      ANDAPHARM's performance of its obligations under this Agreement.

      (b) AUTHORITY. ANDAPHARM warrants, represents and covenants that ANDAPHARM
      has the legal right to enter into this Agreement and perform its
      obligations hereunder. In addition, the undersigned signatory for
      ANDAPHARM represents and warrants that he has been duly authorized to sign
      this Agreement on behalf of ANDAPHARM and he/she further represents that
      all requisite corporate action has been taken on the part of ANDAPHARM to
      approve this Agreement.

      (c) REGULATORY COMPLIANCE. ANDAPHARM will comply with all applicable
      United States and state laws, statutes, rules, and regulations, including
      applicable current FDA guidelines, in the performance of work under this
      Agreement. Without limitation, ANDAPHARM shall be responsible for
      obtaining all necessary permissions and manufacturing licenses for the
      manufacture of Product, in accordance with the applicable United States
      and state laws, statutes, rules, and regulations;

      (d) CGMP COMPLIANCE. All manufacturing under this Agreement will be
      conducted in accordance in all respects with cGMP;

      (e) DISBARMENT. To the best of ANDAPHARM's knowledge, it has not and will
      not use the services of any persons debarred under 21 U.S.C. Section
      335(a) or (b) in any capacity associated with or related to the
      manufacture of the Product. ANDAPHARM also warrants that neither ANDAPHARM
      nor any of its officers or employees has been convicted of a felony under
      the U.S. federal law for conduct relating to the

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        7
<PAGE>

      development or approval, including the process for development or
      approval, of any drug product, new drug application or abbreviated new
      drug application and neither ANDAPHARM nor any of its officers or
      employees has been convicted of a felony under the U.S. federal law for
      conduct relating to the regulation of any product under the Federal Food,
      Drug and Cosmetic Act. If required, ANDAPHARM shall provide for FDA
      submission a standard "Debarrment Certification" upon request of
      BRECKENRIDGE.

4.4   SURVIVAL. The representations and warranties set forth in this Agreement
      shall survive any termination or expiration of this Agreement for any
      reason for a period of [*] years following any such termination or
      expiration. Any claim based in whole or part upon any breach of
      representation or warranty must be brought within such [*] period.

                         ARTICLE 5 - REGULATORY MATTERS

5.1   REGULATORY DOCUMENTATION. ANDAPHARM shall make available for BRECKENRIDGE
      to inspect all licenses and permits necessary for BRECKENRIDGE to insure
      it has met its regulatory requirements. BRECKENRIDGE may not remove any
      documentation from ANDAPHARM without ANDAPHARM's knowledge, and will not
      allow any documents marked as confidential to be shown to other parties
      without ANDAPHARMs consent; provided such information is not already in
      the public domain; known by that party prior to any review, or required to
      continue compliance with any regulatory agency.

5.2   PRODUCT COMPLAINTS. Each party shall immediately inform the other in
      writing of quality, health or safety related concerns or inquiries that
      raise potentially serious and unexpected quality, health or safety
      concerns as to any of the Products. All such other information not
      involving any of the above shall be transmitted to the other party within
      [*] business days following receipt. BRECKENRIDGE shall be responsible for
      receiving, recording and responding to all inquiries or complaints from
      customers, including alleged adverse drug events relating to the Product.
      Each Party agrees to cooperate with the other Party and to provide all
      information reasonably necessary to investigate and respond to any such
      inquiries or complaints and each Party agrees to keep the other Party
      regularly and promptly informed of any complaints it receives relating to
      the Product and to notify the other Party of any adverse drug event
      reports coming to its attention during the term of this Agreement.

                           ARTICLE 6 - INDEMNIFICATION

6.1   INDEMNIFICATION. BRECKENRIDGE shall, at its sole cost and expense, defend,
      indemnify and hold ANDAPHARM and its affiliates and their respective
      officers, directors, agents and employees harmless from and against any
      third-party losses, claims, liabilities, obligations, expenses and/or
      damages (collectively, "Claim(s)") to the extent that such Claims arise
      out of or in connection with, result from, or are caused by: (i)
      BRECKENRIDGE or any of BRECKENRIDGE's Personnel's gross negligence,
      willful misconduct or fraud in connection with the marketing, sale, or
      distribution of the Product as relating to this Agreement; (ii) any breach
      by BRECKENRIDGE of any of

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        8
<PAGE>

      its representations, terms, obligations, warranties or covenants contained
      in this Agreement; (iii) any allegation that any of the Products, or any
      aspect thereof, infringes upon or violates any patent, copyright, trade
      secret, trademark or other proprietary right of any third party relating
      to the marketing, sale, or distribution of the Product as relating to this
      Agreement; or (iv); PROVIDED, HOWEVER, that BRECKENRIDGE shall have no
      liability or indemnification obligations hereunder to the extent any such
      Claim is caused by the gross negligence, willful misconduct or fraud of
      ANDAPHARM, its affiliates or their respective officers, directors, agents
      and/or employees. Any and all legal-related matters and costs triggered by
      this provision shall be undertaken and incurred, respectively, solely
      through counsel selected and managed by BRECKENRIDGE, in its sole
      discretion, who shall assume sole direction and control of such legal
      matters. ANDAPHARM agrees to fully cooperate in the defense of any such
      Claims. Breckenridge shall be obligated under this provision so long as
      Andapharm notifies Breckenridge within ten (10) days of learning of any
      Claims, or cease and desist notices related thereto, which would trigger
      Breckenridge's obligations hereunder. The indemnification rights set forth
      in this Section 4.4 are in addition to, and shall not limit in any way,
      any rights to action or remedies that the parties may have in law or
      equity.

6.2   INDEMNIFICATION. ANDAPHARM shall, at its sole cost and expense, defend,
      indemnify and hold BRECKENRIDGE and its affiliates and their respective
      officers, directors, agents and employees harmless from and against any
      third-party losses, claims, liabilities, obligations, expenses and/or
      damages (including without limitation reasonable attorneys'
      fees)(collectively, "Claim(s)") to the extent that such Claims arise out
      of or in connection with, result from, or are caused by: (i) ANDAPHARM or
      any of ANDAPHARM's Personnel's gross negligence, willful misconduct or
      fraud in connection with the execution and/or performance of this
      Agreement, including, without limitation, the manufacturing, packaging,
      and supply of the Product; (ii) any breach by ANDAPHARM of any of its
      representations, terms, obligations, warranties or covenants contained in
      this Agreement; (iii) any allegation that any of the Products, or any
      aspect thereof, infringes upon or violates any patent, copyright, trade
      secret, trademark or other proprietary right of any third party relating
      to the manufacture, packaging, and supply of the Product; PROVIDED,
      HOWEVER, that ANDAPHARM shall have no liability or indemnification
      obligations hereunder to the extent any such Claim is caused by the gross
      negligence, willful misconduct or fraud of BRECKENRIDGE, its affiliates or
      their respective officers, directors, agents and/or employees. Any and all
      legal-related matters and costs triggered by this provision shall be
      undertaken and incurred, respectively, solely through counsel selected and
      managed by ANDAPHARM, in its sole discretion, who shall assume sole
      direction and control of such legal matters. BRECKENRIDGE agrees to fully
      cooperate in the defense of any such Claims. Andapharm shall be obligated
      under this provision so long as Breckenridge notifies Andapharm within ten
      (10) days of learning of any Claims, or cease and desist notices related
      thereto, which would trigger Andapharm's obligations hereunder. The
      indemnification rights set forth in this Section 4.5 are in addition to,
      and shall not limit in any way, any rights to action or remedies that the
      parties may have in law or equity.

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        9
<PAGE>

6.3   INSURANCE.

            (a) ANDAPHARM represents and warrants that it has obtained and shall
      at all times during the term of this Agreement maintain at its own cost
      and expense, in respect to its performance hereunder: (a) [      *      ];
      (b) worker's compensation insurance in accordance with the statutory
      requirements of Florida; and (c) [       *       ].

            (b) BRECKENRIDGE represents and warrants that it has obtained and
      shall at all times maintain at its own cost and expense [       *       ]
      Breckenridge will supply ANDAPHARM with a certificate of insurance to
      evidence such coverage, upon request.

6.4   LIMITATION OF LIABILITY. The liability of either party to the other for
      any claim arising out of contract, negligence or strict liability in tort,
      or any other claim relating to this Agreement, shall be limited to the
      actual damages suffered or incurred by a party. Except for indemnification
      for infringement and the cost of cover, in no event shall either party be
      liable for incidental or consequential damages, loss of business or
      profits, special or indirect damages of any nature whatsoever even if it
      has been advised of the possibility of such damages. The limitations of
      liability stated in this Agreement form an essential basis of the bargain
      between the parties and apply regardless of whether any limited remedy
      hereunder fails of its essential purpose. Nothing herein shall limit any
      right of recovery under any policy of insurance or any bond.

                          ARTICLE 7 - TERMS, TERMINATION

7.1   TERM. This Agreement shall become effective as of the date first written
      above and shall remain in full force and effect through the end of the
      Purchase Term, or until earlier terminated as provided herein.

7.2   TERMINATION. This Agreement may be terminated at any time:

      (a)   by either party if the other party fails to remedy and make good any
            default in the performance of any condition or obligation under this
            Agreement within [ * ] days of the date a written notice of default
            is sent to the defaulting party thereof, (OTHER THAN THE FAILURE TO
            PAY ANY AMOUNT DUE UNDER THIS AGREEMENT, FOR WHICH [  *  ] NOTICE
            SHALL BE AVAILABLE EXCEPT AS PROVIDED ELSEWHERE.);

      (b)   by either party upon bankruptcy or insolvency of the other party or
            placing of the business of such party in receivership;

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10
<PAGE>

      (c)   by BRECKENRIDGE upon providing written notice to ANDAPHARM, if
            BRECKENRIDGE and/or ANDAPHARM are prohibited by Federal or State law
            or order from manufacturing or distributing the Products.

      (d)   by ANDAPHARM in accordance with Article 3.8;

      (e)   by either party if a price adjustment cannot be mutually agreed upon
            in accordance with Article 2.2.

7.3   WAIVER. Failure to terminate this Agreement following a breach or failure
      to comply with the terms and conditions of this Agreement shall not be
      deemed a waiver of the non breaching party's defenses, rights or causes of
      action arising from such or any future breach or noncompliance.

                             ARTICLE 8 - ASSIGNMENT

8.1   ASSIGNMENT. This Agreement may not be assigned by BRECKENRIDGE or
      ANDAPHARM or the obligations of BRECKENRIDGE and ANDAPHARM delegated
      hereunder without the prior written consent of BRECKENRIDGE or ANDAPHARM,
      which shall not be unreasonably withheld. Notwithstanding the foregoing,
      BRECKENRIDGE or ANDAPHARM may assign any or all of its rights and
      obligations under this Agreement, without obtaining the other's consent,
      only in the event of the merger or consolidation of BRECKENRIDGE or
      ANDAPHARM with another entity or the purchase by another entity of all or
      substantially all of the assets of BRECKENRIDGE or ANDAPHARM.
      Notwithstanding the foregoing, this Agreement shall survive the merger or
      consolidation of BRECKENRIDGE or ANDAPHARM with another entity or the
      purchase by another entity of all or substantially all of the assets of
      BRECKENRIDGE or ANDAPHARM and BRECKENRIDGE and ANDAPHARM agrees to give
      each other thirty (30) days' notice of any such merger, consolidation or
      purchase, if and to the extent it may do so under applicable securities
      laws.

                            ARTICLE 9 - FORCE MAJEURE

9.1   FORCE MAJEURE. No failure or omission by the parties in the performance of
      any obligation according to this Agreement shall be deemed a breach of
      this Agreement or create any liability if the same shall arise from any
      cause or causes beyond the control of the party, including, but not
      limited to, strikes, riots, war, acts of terrorism, acts of God, invasion,
      fire, explosion, floods, delay of carrier, shortage or failure in the
      supply of materials, energy shortage and acts of government or
      governmental agencies or instrumentalities.

9.2   OBLIGATIONS OF THE PARTIES IN CASE OF FORCE MAJEURE. In the event that due
      to force majeure either party hereto shall be delayed or hindered in or
      prevented from the performance of its duties or doing acts required under
      the terms of this Agreement, the performance of such act, except for the
      obligation to pay amounts due under this Agreement, shall be excused for
      the period of the delay but in no event longer than 6 months, at which
      time any party may terminate the agreement. Notwithstanding the
      aforementioned, the party subject to force majeure shall take all
      reasonable steps to

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       11
<PAGE>

      resolve the condition(s) forming the basis of force majeure.

                           ARTICLE 10 - MISCELLANEOUS

10.1  GOVERNING LAW. This Agreement shall be governed by, and construed in
      accordance with, the laws of the State of Florida (without regard for
      conflict rules thereof) and the United States.

10.2  SEVERABILITY. Should any section, or portion, of this Agreement be held
      invalid by reason of any law, statute or regulation existing now or in the
      future in any jurisdiction by any court of competent authority or by
      legally enforceable directive of any governmental body, then such section
      or portion thereof shall be validly reformed so as to approximate the
      intent of the parties as nearly as possible and, if unreformable, shall be
      deemed divisible and deleted with respect to such jurisdiction; this
      Agreement shall not otherwise be affected.

10.3  ENTIRE AGREEMENT. The terms and provisions contained in this Agreement,
      including the Exhibits hereto, constitute the entire agreement between the
      parties and shall supersede all previous communications, representations,
      agreements or understandings, either oral or written, between the parties
      with respect to the subject matter hereof, including the Original Supply
      Agreement. No agreement or understanding varying or extending this
      Agreement shall be binding upon either party hereto, unless set forth in a
      writing which specifically refers to this Agreement, signed by duly
      authorized officers or representatives of the respective parties, and the
      provisions hereof not specifically amended thereby shall remain in full
      force and effect. By execution of this agreement, the parties further
      agree to waive and release all claims, unknown or unknown, it had or may
      have had against the other party relating to the Original Supply
      Agreement.

10.4  WAIVER. The rights and remedies of the parties to this Agreement are
      cumulative and not alternative. Neither the failure nor any delay by any
      party in exercising any right, power or privilege under this Agreement
      will operate as a waiver of any such right, power or privilege, and no
      single or partial exercise of any such right, power or privilege will
      preclude any other or further exercise of such right, power or privilege
      or the exercise of any other right, power or privilege.

10.5  NOTICES. All notices hereunder shall be deemed to have been delivered if
      by certified mail, return receipt requested, or if sent by facsimile, as
      follows.

      If to BRECKENRIDGE:
      Breckenridge Pharmaceutical, Inc.
      15 Massirio Drive
      Suite 201
      Berlin, CT 06037
      ATTN: General Counsel

      With Copy to VP Business Development

      If to ANDAPHARM:

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       12
<PAGE>

      ANDAPHARM LLC
      5315 NW 35th Terrace
      Fort Lauderdale, Florida 33309
      ATTN: Charles J. Duffy, III, Esquire

      With a copy to Steven Getraer, CFO and John Copanos, Vice President,
      Business Development

10.6  SURVIVAL. The provisions of Paragraph 4, Paragraph 6 & 10 of the Agreement
      shall survive the termination of this Agreement.

10.7  COUNTERPARTS. This Agreement may be executed in two or more counterparts,
      each of which will be deemed to be an original of this Agreement and all
      of which, when taken together, shall be deemed to constitute one and the
      same agreement. Any party to this Agreement may deliver an executed copy
      hereof by facsimile transmission, including via PDF/email, to another
      party hereto and any such delivery shall have the same force and effect as
      any other delivery of a manually signed copy of this Agreement.

10.8  EXHIBITS, SCHEDULES. Any exhibits and schedules to this Agreement are
      hereby incorporated by reference into and made a part of this Agreement.

10.9  SIGNATURE WARRANTY. It is understood and agreed by the Parties that each
      represents and warrants to the other that the individual signing this
      Agreement on behalf of the Party is their duly authorized representative
      and that such individual's signature binds the Party represented to the
      terms of this Agreement.

10.10 ARBITRATION. Any and all disputes or claims arising or out of this
      Agreement shall be resolved by binding arbitration utilizing the American
      Arbitration Association and under the American Arbitration Association's
      commercial industry rules and to be held in the State of Florida. The
      decision of any arbitration panel shall be binding on the parties and
      enforceable in any court of competent jurisdiction

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers on the day and year first set forth
above.

ANDAPHARM LLC                        BRECKENRIDGE PHARMACEUITCAL, INC.

By: /s/ Steven Getraer               By: /s/ Larry J. Lapila
    ------------------------------       ----------------------------
Name:   Steven Getraer               Name:   Larry J. Lapila
Title:  Chief Financial Officer      Title:  Vice President Business Development

Dated:                               Dated: 2/29/08

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       13
<PAGE>

                                    EXHIBIT A

--------------------------------------------------------------------------------
                      PRODUCT DESCRIPTION AND SPECIFICATION
--------------------------------------------------------------------------------

[

                                        *

                                                                               ]

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       14
<PAGE>

--------------------------------------------------------------------------------
                         PRICING AND MINIMUM QUANTITIES
--------------------------------------------------------------------------------

[

                                        *

                                                                               ]

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       15
<PAGE>

                                    EXHIBIT B

                                                             ------------------

                               ------------------
                                 PURCHASE ORDER
                               ------------------

                                                       -----------------
                                                       P/O NUMBER   PAGE
[LOGO] BRECKENRIDGE PHARMACEUTICAL, INC.               -----------------
       1141 South Rogers Circle, Suite 3
       Boca Raton, FL 33487                   ----------------------------------
       561-443-3314 fax 561-989-0819          P/O DATE  ORDER TYPE CHANGE/CANCEL
                                              ----------------------------------

ORDERED                                 SHIP
   FROM                                   TO

--------------------------------------------------------------------------------
        BUYER         TERMS       ACKNOW-    CONFIRM    FOB    SHIP VIA     COL/
                                  LEDGE                                     PPD
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
LINE  QUANTITY
 NO.  ORDERED          OUR ITEM NUMBER      YOUR ITEM   PRICE/  REQUESTED CHANGE
     BLANKET TYPE  U/M DESCRIPTION/COMMENTS NUMBER      UNIT    DATE      CANCEL
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
                  COMMENTS

                  --------------------------------------------------------------

                            ORDERED BY -----------------------------------------

* PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN
APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                         16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]